Trade PLX anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Protalix BioTherapeutics, Inc. (PLX) is trading at US$2.58, down 1.26% today as of Aug 28, 09:32 EDT. The company has a market capitalisation of US$191.76M. Over the past 52 weeks, PLX has traded between US$1.52 and US$3.19. On Syfe you can trade PLX with $0 commission and add it to your watchlist.
| Previous close | US$2.61 |
|---|---|
| Market cap | US$191.76M |
| P/E ratio | 23.41 |
| 52-week range | US$1.52 – US$3.19 |
| Volume | 1.28M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Protalix BioTherapeutics, Inc.
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.
Year: 1996
Top Midday Decliners
Mar 18, 6:03 PM · MT Newswires
Protalix BioTherapeutics, Inc. (PLX) stock is trading at US$2.58, -1.26% from the previous close of US$2.61.
The market cap for Protalix BioTherapeutics, Inc. (PLX) stock is approximately US$191.76M.
The price-to-earnings ratio for Protalix BioTherapeutics, Inc. (PLX) is 23.41, based on the latest reported earnings.
The 52-week high for Protalix BioTherapeutics, Inc. (PLX) stock is US$3.19.
The 52-week low for Protalix BioTherapeutics, Inc. (PLX) stock is US$1.52.
Protalix BioTherapeutics, Inc. (PLX) does not currently pay a dividend.
Stay on top of PLX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
